For those who dont want to read the whole article:
Cellmid, another Australian biotech company developing overseas technology — this time from Japan — has adopted a novel approach to generating revenue for its anti-cancer products. When the GFC choked access to capital, Cellmid launched a natural hair loss drug. Last year Cellmid’s hair loss business covered 65 per cent of its cancer drug expenditure.
Chief executive Maria Halasz says the experience showed the company’s competitive advantage to the market. “Not only are we good product developers in pharmaceuticals, we are also prudent managers (who) can reduce risk.”
10 to watch • Sydney-based Cellmid will next year trial a drug to treat multiple solid tumours. “We consider ourselves among the 20 per cent of oncology drugs that have real breakthrough potential,” says chief executive Maria Halasz.
Great to see some exposure in mainstream media.
- Forums
- ASX - By Stock
- AN1
- CDY in top 10 Biotech companies to watch
CDY in top 10 Biotech companies to watch, page-2
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online